(Q34535213)

2 August 2017

1 reference

title

Comparative clinical pharmacology and pharmacokinetic interactions of aromatase inhibitors (English)

1 reference

2 August 2017

1 reference

1 reference

Boeddinghaus IM

1

1 reference

PubMed ID

11850211

2 August 2017

Dowsett M

series ordinal

2

1 reference

PubMed ID

11850211

2 August 2017

language of work or name

1 reference

1 December 2001

1 reference

The Journal of Steroid Biochemistry and Molecular Biology

2 August 2017

1 reference

2 August 2017

79

1 reference

2 August 2017

1-5

1 reference

2 August 2017

85-91

1 reference

Anastrozole versus megestrol acetate in the treatment of postmenopausal women with advanced breast carcinoma: results of a survival update based on a combined analysis of data from two mature phase III trials. Arimidex Study Group

2 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2801%2900126-1

7 January 2021

Letrozole, a new oral aromatase inhibitor for advanced breast cancer: double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2801%2900126-1

7 January 2021

Exemestane is superior to megestrol acetate after tamoxifen failure in postmenopausal women with advanced breast cancer: results of a phase III randomized double-blind trial. The Exemestane Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2801%2900126-1

7 January 2021

Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability study

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2801%2900126-1

7 January 2021

Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. Arimidex Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2801%2900126-1

7 January 2021

Mechanism and inhibition of cytochrome P-450 aromatase

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2801%2900126-1

7 January 2021

Theoretical considerations for the ideal aromatase inhibitor

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2801%2900126-1

7 January 2021

Adrenal suppression with aminoglutethimide. II. Differential effects of aminoglutethimide on plasma androstenedione and estrogen levels

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2801%2900126-1

7 January 2021

Suppression of plasma 6-keto-prostaglandin F1 alpha and 13,14-dihydro-15-keto-prostaglandin F2 alpha by aminoglutethimide in advanced breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2801%2900126-1

7 January 2021

Compensatory Increase in TSH Secretion without Effect on Prolactin Secretion in Patients Treated with Aminoglutethimide

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2801%2900126-1

7 January 2021

Aminoglutethimide stimulates extra adrenal delta-4-androstenedione production

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2801%2900126-1

7 January 2021

The Effect of an Aromatase Inhibitor, 4-Hydroxy-4-Androstene- 3,17-Dione, On Estrogen-Dependent Processes in Reproduction and Breast Cancer11

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2801%2900126-1

7 January 2021

6-Methylenandrosta-1,4-diene-3,17-dione (FCE 24304): a new irreversible aromatase inhibitor

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2801%2900126-1

7 January 2021

Potency and selectivity of the non-steroidal aromatase inhibitor CGS 16949A in postmenopausal breast cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2801%2900126-1

7 January 2021

Double-blind, randomised, multicentre endocrine trial comparing two letrozole doses, in postmenopausal breast cancer patients1Accepted as a poster presentation to the 34th Annual Meeting of the American Society of Clinical Oncology, May 1998, Los Ang

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2801%2900126-1

7 January 2021

The aromatase inhibitor letrozole in advanced breast cancer: Effects on serum insulin-like growth factor (IGF)-I and IGF-binding protein-3 levels

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2801%2900126-1

7 January 2021

Influence of tamoxifen, aminoglutethimide and goserelin on human plasma IGF-I levels in breast cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2801%2900126-1

7 January 2021

The effect of endocrine therapy with medroxyprogesterone acetate, 4-hydroxyandrostenedione or tamoxifen on plasma concentrations of insulin-like growth factor (IGF)-I, IGF-II and IGFBP-1 in women with advanced breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2801%2900126-1

7 January 2021

Effect of two 4-hydroxyandrostenedione doses on serum insulin-like growth factor I levels in advanced breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2801%2900126-1

7 January 2021

Effect of acute and chronic administration of tamoxifen on GH response to GHRH and on IGF-I serum levels in women with breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2801%2900126-1

7 January 2021

Oestrogenic effects of adjuvant tamoxifen in postmenopausal breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2801%2900126-1

7 January 2021

Alterations in the production rate and the metabolism of oestrone and oestrone sulphate in breast cancer patients treated with aminoglutethimide

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2801%2900126-1

7 January 2021

Relations between sex hormones, sex hormone binding globulin, insulin-like growth factor-I and insulin-like growth factor binding protein-1 in post-menopausal breast cancer patients.

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2801%2900126-1

7 January 2021

A randomized, open, parallel-group trial to compare the endocrine effects of oral anastrozole (Arimidex) with intramuscular formestane in postmenopausal women with advanced breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2801%2900126-1

7 January 2021

Vorozole results in greater oestrogen suppression than formestane in postmenopausal women and when added to goserelin in premenopausal women with advanced breast cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2801%2900126-1

7 January 2021

New collagens, new concepts

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2801%2900126-1

7 January 2021

Letrozole, a new oral aromatase inhibitor: randomised trial comparing 2.5 mg daily, 0.5 mg daily and aminoglutethimide in postmenopausal women with advanced breast cancer. Letrozole International Trial Group (AR/BC3).

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2801%2900126-1

7 January 2021

Randomized trial of tamoxifen alone or combined with aminoglutethimide and hydrocortisone in women with metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2801%2900126-1

7 January 2021

The effect of anastrozole on the pharmacokinetics of tamoxifen in post-menopausal women with early breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2801%2900126-1

7 January 2021

Antagonism of aminoglutethimide and danazol in the suppression of serum free oestradiol in breast cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2801%2900126-1

7 January 2021

Aromatase inhibition by R 76713: experimental and clinical pharmacology

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2801%2900126-1

7 January 2021

Resistance of the ovary to blockade of aromatization with aminoglutethimide

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2801%2900126-1

7 January 2021

Endocrine and Therapeutic Effects of Aminoglutethimide in Premenopausal Patients with Breast Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2801%2900126-1

7 January 2021

Aminoglutethimide in the treatment of premenopausal patients with metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2801%2900126-1

7 January 2021

The influence of aminoglutethimide and its analogue rogletimide on peripheral aromatisation in breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2801%2900126-1

7 January 2021

The influence of intramuscular 4-hydroxyandrostenedione on peripheral aromatisation in breast cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2801%2900126-1

7 January 2021

The influence of CGS 16949A on peripheral aromatisation in breast cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2801%2900126-1

7 January 2021

Influence of anastrozole (Arimidex), a selective, non-steroidal aromatase inhibitor, on in vivo aromatisation and plasma oestrogen levels in postmenopausal women with breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2801%2900126-1

7 January 2021

10.1016/S0960-0760(01)00126-1

Identifiers

DOI

1 reference

2 August 2017

1 reference

PubMed ID

11850211